MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.60% | 14.88% | 14.31% | 12.56% | 24.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.60% | 14.88% | 14.31% | 12.56% | 24.86% |
| Cost of Revenue | 4.34% | 30.94% | 34.75% | 16.57% | 28.48% |
| Gross Profit | 8.55% | -12.78% | -15.08% | 4.91% | 17.11% |
| SG&A Expenses | -8.22% | -4.13% | -3.53% | -17.14% | 3.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 30.76% | -9.98% | 204.89% | 764.86% | 0.83% |
| Total Operating Expenses | -1.06% | 14.33% | 16.45% | 0.25% | 16.17% |
| Operating Income | 28.52% | -11.32% | -28.92% | 39.13% | 9.71% |
| Income Before Tax | 23.89% | 34.65% | 37.66% | 47.34% | 20.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.89% | 33.14% | 36.37% | 46.28% | 19.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.89% | 33.14% | 36.37% | 46.28% | 19.27% |
| EBIT | 28.52% | -11.32% | -28.92% | 39.13% | 9.71% |
| EBITDA | 25.60% | -39.30% | -75.72% | 44.25% | 13.50% |
| EPS Basic | 26.04% | 35.65% | 39.11% | 48.44% | 29.41% |
| Normalized Basic EPS | 30.97% | -11.69% | -27.40% | 41.91% | 20.98% |
| EPS Diluted | 26.04% | 35.65% | 39.11% | 48.44% | 29.41% |
| Normalized Diluted EPS | 30.97% | -11.69% | -27.40% | 41.91% | 20.98% |
| Average Basic Shares Outstanding | 2.55% | 4.12% | 4.33% | 4.76% | 13.18% |
| Average Diluted Shares Outstanding | 2.55% | 4.12% | 4.33% | 4.76% | 13.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |